Austria 1652011
-
Upload
sherifkamal -
Category
Health & Medicine
-
view
698 -
download
0
description
Transcript of Austria 1652011
![Page 1: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/1.jpg)
1 Sherif kamal 2010
![Page 2: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/2.jpg)
Role of Pharmacists in Pediatric Oncology
Sherif Kamal
DPS Director
![Page 3: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/3.jpg)
Sherif kamal 2010
![Page 4: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/4.jpg)
Sherif kamal 2010
![Page 5: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/5.jpg)
Sherif kamal 2010
Clinical Pharmacy - Egypt
![Page 6: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/6.jpg)
Sherif kamal 2010
Clinical Pharmacy Story - Egypt
• Implementation
• Measurement
• Sharing
![Page 7: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/7.jpg)
NCI/Naser/Pyramids/Zagazig/
Tanta
Menya Clinical
Pharmacy Program Assuit
Clinical course
![Page 8: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/8.jpg)
Sherif kamal 2010
![Page 9: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/9.jpg)
Challenges
![Page 10: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/10.jpg)
Value of the Clinical Pharmacist
• 1 $ for Clinical Pharmacy = 14 $ ROI
• 1 $ for Patient Education = 4 $ ROI
• IV saving
• TDM saving
• Hospital Mortality
![Page 11: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/11.jpg)
Our Challenge
In Egypt, In Egypt,
8,000 children8,000 children
are diagnosed are diagnosed
with cancerwith cancer
every yearevery year
![Page 12: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/12.jpg)
Change
![Page 13: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/13.jpg)
Change
NCI CCHE
![Page 14: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/14.jpg)
• Change – Design,– Functionality– space
![Page 15: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/15.jpg)
15 Sherif kamal 2010
![Page 16: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/16.jpg)
Vision
• The vision of the CCHDPS is to enhance patients' quality of life And to obtain positive patient outcomes.
![Page 17: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/17.jpg)
Mission
• The DPS will provide a state-of-art comprehensive pharmaceutical care that is patient centered; focusing on evidence based innovative techniques and scientific research, to reduce morbidity and mortality of children with cancer.
![Page 18: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/18.jpg)
![Page 19: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/19.jpg)
57357 Children’s Cancer Hospital
Cairo, Egypt
6-10 June, 2010
![Page 20: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/20.jpg)
![Page 22: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/22.jpg)
![Page 23: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/23.jpg)
Pharmacy Statistics• Items charged = 70,921• MAE = 62,137• Total no. of orders = 30,100• Doses = 91,142• Patient transaction = 4216• Days of medication service = 5229• IV orders = 15,438• IV dose = 31491• Lab= 552• Working hours = >13000• Total no. of trainees =210
Sherif kamal 2010
![Page 24: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/24.jpg)
Org Structure
![Page 25: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/25.jpg)
CCHE DPS Components1. I.V admixture2. Patient Services3. Ambulatory Care (OPD/DC/MSC) 4. TPN5. Dispensing 6. Drug Information 7. Therapeutic Drug Monitoring 8. Nuclear Pharmacy (New Service)9. Critical Care Pharmacy (New Service)10. Pain Service (New Service) 11. Controlled Substances 12. Neuro-Care Pharmacy (New Service) 13. Pharmacoeconomic services 14. Drug Procurement Office 15. Pharmacoinformatics 16. Quality Management 17. Safe handling of Hazards Material and Waste management 18. Clinical Trials 19. Newsletter and websites
![Page 26: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/26.jpg)
Drug Procurement Office Tender Document
![Page 27: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/27.jpg)
IV admixture
• IV prep
• IV Mix
• TPN
• IV check
![Page 28: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/28.jpg)
Dispensing
• Out Patient
• In Patient
• Day Care
• Patient Education
![Page 29: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/29.jpg)
Assessing Dispensing Errors
![Page 30: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/30.jpg)
Patient Education
Sherif kamal 2010
![Page 31: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/31.jpg)
WHENEVER POSSIBLE USE PATIENT EDUCATION MATERIAL
Imatinib
Labels
![Page 32: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/32.jpg)
PATIENT EDUCATION MATERIAL
Brochures
![Page 33: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/33.jpg)
Wall Papers
PATIENT EDUCATION MATERIAL
![Page 34: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/34.jpg)
Wall Papers in the Waiting Area
![Page 35: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/35.jpg)
Patient BookletsPATIENT EDUCATION MATERIAL
![Page 36: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/36.jpg)
Patient Flyers
PATIENT EDUCATION MATERIAL
![Page 37: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/37.jpg)
![Page 38: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/38.jpg)
![Page 39: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/39.jpg)
![Page 40: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/40.jpg)
Sherif kamal 201040
![Page 41: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/41.jpg)
![Page 42: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/42.jpg)
Assessing Quality of Patient Education
![Page 43: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/43.jpg)
Assessment of patient adherence
• Objective:– This study is an attempt to examine patient
compliance.
• Specific objective: – to investigate the extent to which a patient's
behavior taking medications.– To investigate adherence to physician's
orders.
![Page 44: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/44.jpg)
Assessment of patient adherence
![Page 45: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/45.jpg)
Round 10:1
![Page 47: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/47.jpg)
Case
• Name : AS• Presented on 17/12/2007- ICU 7 pm • TLC 390 000• LDH 15438
Management on 17/12Hydration Urine PH = 6S.cr 4.1Decision to give Rasburicase 0.2 mg /kg G-6PD tested
47 Sherif kamal 2010
![Page 48: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/48.jpg)
Case L4• Name : NI• Presented on 7/2/2008- ICU 16:00
pm • TLC 23 500 • LDH 2283 IU/l
48 Sherif kamal 2010
![Page 50: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/50.jpg)
Effectiveness of Ondansetron
![Page 51: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/51.jpg)
First ICU Clinical Pharmacy
• 37% higher mortality and 14.8% longer ICU stays
• 184 extra deaths, 59,429 extra hospital days, $215,397,354 extra total Medicare charges, and $26,363,674 extra drug charges,"
MacLaren R and Bond CA. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events. Pharmacotherapy. 2009; 29:761-8.
![Page 52: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/52.jpg)
52 Sherif kamal 2010
![Page 53: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/53.jpg)
Stewardship program
![Page 54: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/54.jpg)
![Page 55: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/55.jpg)
![Page 56: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/56.jpg)
Discussion and recommendations
![Page 57: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/57.jpg)
Discussion and recommendations
![Page 58: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/58.jpg)
Discussion and recommendations
![Page 59: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/59.jpg)
Restricted drug List
![Page 60: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/60.jpg)
60 Sherif kamal 2010
![Page 61: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/61.jpg)
Sherif kamal 2010
![Page 62: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/62.jpg)
Sherif kamal 2010
![Page 63: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/63.jpg)
63 Sherif kamal 2010
![Page 64: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/64.jpg)
Sherif kamal 2010
Dexamethasone Use inBT
![Page 65: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/65.jpg)
Sherif kamal 2010
My Experience with Brain T in a baby Girl
![Page 66: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/66.jpg)
Role of Pharmacists in Protocol Management
![Page 67: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/67.jpg)
PK lab
![Page 68: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/68.jpg)
Sherif kamal 2010
![Page 69: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/69.jpg)
Sherif kamal 2010
![Page 70: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/70.jpg)
Sherif kamal 2010
![Page 71: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/71.jpg)
71 Sherif kamal 2011
![Page 72: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/72.jpg)
RELATION BETWEEN VALPROIC ACID ADMINSTRATION AND THE INCIDENCE OF THROMBOCYTOPENIA
• Introduction: Valproic acid is used in our setting as antiepileptic drug either alone or in combination with other antiepileptic drugs.Thromhocytopenia in association with valproic acid therapy has been reported in patients of various ages with incidences ranging from 1 to 32%. Regarding the pathophysiology of the Thromhocytopenia associated with valproic acid therapy, there is evidence to suggest that valproic acid can evoke an immune response with the production of antibodies directed against platelets. Sandler described circulating and bound platelet antibodies of the IgM type . Especially in pediatric oncology setting where thromhocytopenia is common it is very essential to study this association.
• Materials & Methods: To evaluate this association in a pediatric population, we retrospectively studied 55 children treated with valproic acid(VPA) at our institution in April 2010.The patient medical files were reviewed The Incidence of thrombocytopenia were recorded based onthat Thrombocytopenia was defined as a platelet count ~200 x 103/mm3.The valproic acid levels of these patients were also recorderded in this period of time .
• Results: We retrospectively studied children treated with valproic acid(VPA) at our in April 2010. The Incidence of thrombocytopenia in Valproic acid population was 17% which is within the range of the benchmark .Only 50 % of the cases having thrombocytopenia showed normal therapeutic level values .25 % of the patients having thrombocytopenia showed higher level of valproic acid and 25% showed subtherapeutic levels and required increase in dose .
• Discussion, Conclusion: The Incidence of thrombocytopenia in Valproic acid population is less than 17% which is within the range of the benchmark .The correlation between the incidence of thrombocytopenia and the drug level need to be further studied and this is next on our agenda.But we recommend that platelet counts should be closely monitored in patients recieving valproic acid especially in patients were we are going to increase the dose due to subtherapeutic levels.
![Page 73: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/73.jpg)
Pharmacy Automation
![Page 74: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/74.jpg)
57357 - Vital Signs
Metric NameTotalDaily Average
Appointments 15,222491
Registrations 11,970386
Charts Open209,8796,770
Orders239,0887,713
Inbound Interfaces 17,323642
Outbound Interface45,7221,475
Work Load
*August 2010 Monthly Cumulative Figures
![Page 75: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/75.jpg)
24 Hour Snap Shot in 57357 Metric Value
Logins 3,421
Nurse Assessments / Forms Completed 2,001
PAL Opened 828
All Orders Written 10,177
Total Medication Orders 4,033
Total Medications Administered 4,379
Lab Orders 4,868
Total Charts Opened 7,460
Physicians – PowerNotes Documented 263
Physicians – PowerNotes Signed 301
Alerts Fired 411
*Data Captured Thursday September 16th 2010
![Page 76: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/76.jpg)
76 Sherif kamal 2010
![Page 77: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/77.jpg)
4169
![Page 78: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/78.jpg)
![Page 79: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/79.jpg)
![Page 80: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/80.jpg)
Newsletter
![Page 81: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/81.jpg)
Sherif kamal 2010
Vincristine
• Lookalike /Soundalike
• TALLman :vinCRIstine====vinBLAstine
• Peripheral neuropathy
• Bilrubin
• Cell cycle specific
• Extravasation
Role Of Pharmacists as patient Safety Officers
![Page 82: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/82.jpg)
LASA
Sherif kamal 2011
![Page 83: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/83.jpg)
Sherif kamal 2011
![Page 84: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/84.jpg)
Sherif kamal 2010
![Page 85: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/85.jpg)
Sherif kamal 2010
Triple ITH
• 3 drugs together?
• Package (Filter ,Alcohol swabs,dressing)
• When to give /HDMTX?
• Error
![Page 86: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/86.jpg)
Sherif kamal 2010
What To Do?
• Color Coding
• VCR as IV bag
![Page 87: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/87.jpg)
![Page 88: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/88.jpg)
![Page 89: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/89.jpg)
Sherif kamal 2010
![Page 90: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/90.jpg)
Sherif kamal 2010
![Page 91: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/91.jpg)
Sherif kamal 2010
![Page 92: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/92.jpg)
HFMEA
• Cheng C. H. et al. (2010). Applying HFMEA to Prevent Chemotherapy Errors. Journal of Medical Systems. Available at http://www.springerlink.com/content/j47u588376g58p87/fulltext.pdf
• Failure mode and effect analysis (FMEA) is a systematic and prospective risk evaluation method initially adopted in the industrial field.
• It has been widely used by engineers to improve the reliability, quality, and safety of their products and to reduce potential risks. The most important function of FMEA is to identify potential failure modes for each subsystem or component.
Sherif kamal 2010
![Page 93: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/93.jpg)
IHI
Sherif kamal 2010
![Page 94: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/94.jpg)
Sherif kamal 2010
![Page 95: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/95.jpg)
Mucositis Mucositis
II - Accurate number of patients having OM - Accurate number of patients having OM
Which include: category II & IV (NO/YES & YES/YES)Which include: category II & IV (NO/YES & YES/YES)
a) % of mucositis occurrence : 51%
b) Relation to gender: male (60%) & females (40%)
c) Relation to age :
• From 0.6 to 6 years : 50%
• From 7 to 12 years : 24%
• From 13 to 19 years : 26%
![Page 96: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/96.jpg)
Analysis of dataAnalysis of data
e) Relation to prophylaxis :e) Relation to prophylaxis : • 48% of these patients use prophylaxis.
• 52% of these patients don’t use it.
f) Type of prophylaxis :f) Type of prophylaxis :
TypeTypePercentage %Percentage %Hexitol41%
Nystatin76%
Miconazole63%
mouthcare43%
![Page 97: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/97.jpg)
Analysis of dataAnalysis of data
d) Cancer type :d) Cancer type :
• ALL : 37%
• AML : 27%
• NHL : 18%
• OS : 1%
• RMS : 11%
• Others : 3% (ES,RM & WT)
![Page 98: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/98.jpg)
Analysis of dataAnalysis of data
g) Grade of mucositis:g) Grade of mucositis:
gradegradePercentage %Percentage %
G1G110%
G2G224%
G3G310%
G4G410%
HLHL16%
WPWP9%
PIPI9%
PI & CanPI & Can1%
Ulcers on mouthUlcers on mouth8%
![Page 99: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/99.jpg)
Analysis of dataAnalysis of data h) Dose of chemotherapy:h) Dose of chemotherapy:
• The doses of chemotherapy are just before occurrence of OM :
dosesdosesPercentage %Percentage %MTX14%
6-MP9%
VCR14%
CYTRA16%
DOXO18%
DEXA2%
ETOPO7%
CYCLO7%
HC3%
PREDN.06%
ASPARA4%
IFOSF.1%
BETA.06%
CARBO.06%
DAUNO.06%
![Page 100: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/100.jpg)
Sherif kamal 2010
Asparaginase prep
![Page 101: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/101.jpg)
Sherif kamal 2010
Cyclophosphamide
![Page 102: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/102.jpg)
102 Sherif kamal 2010
![Page 103: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/103.jpg)
![Page 104: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/104.jpg)
Tannic Acid as effective Hemostatic agent in pediatric adenocarinoma :A case Study
• Introduction: Standard treatment of profuse bleeding was done using patches of oxidized regenerated cellulose .There are no reports on managing failure of oxidized regenerated cellulose patches .Using tannic acid solution was recommended by the Chief Surgeon in the hospital ,the pharmacy looked up the extemporaneous formulation of tannic acid and followed up the patient .
• Materials & Methods: This was a real time case study in the children cancer hospital Egypt Tannic acid was prepared as a 40% solution in water and was applied to the surgical site three times daily as compresses for 3 month as the patient was on palliative treatment. The number of transfusion before and after using the Tannic acid preparation were studied. The efficacy of the haemostatic activity was measured by the number of blood transfusion and stopping the bleeding.
• Results:
• After the last operation the patient suffered from severe bleeding from the surgical site.
• Patches of oxidized regenerated cellulose was given to control bleeding with no success, where 3 blood transfusions were needed. After using the Tannic acid 40 % the need for transfusion decreased to one transfusion in the first week followed by three weeks without transfusion.
• Discussion, Conclusion: As mentioned by the mother the severe bleeding prevented the efficacy of the Patches of oxidized regenerated cellulose by detaching the patch from the site of bleeding also she noted that the size of surgical site was preventing fitting the patch. The tannic acid 40% preparation in water and was applied to the surgical site three times daily as compresses for 3 month was ver effective in stoping bleeding and improving the quality of life of our patient . The Role of the pharamcists was very clear in following up the case detecting the need for another intervention , searching for evidence for the new intervention ,implementing the intervention then following up and reporting the case.
![Page 105: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/105.jpg)
Monitoring of Toxicity
Sherif kamal 2010105
![Page 106: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/106.jpg)
Amphotericin B vs. Liposomal Ampho B
![Page 107: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/107.jpg)
![Page 108: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/108.jpg)
Tele-Pharmacy
• Using hybrid solutions for maximizing the return on investment from telemedicine in pharmacy education
• 5^th Annual Pediatric Tele-health Colloquium at the 2010 American Telemedicine Association
108 Sherif kamal 2010
![Page 109: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/109.jpg)
![Page 110: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/110.jpg)
110 Sherif kamal 2010
![Page 111: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/111.jpg)
![Page 112: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/112.jpg)
![Page 113: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/113.jpg)
![Page 114: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/114.jpg)
![Page 115: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/115.jpg)
Training
• 15 Orientation Trainee per week
• Sudan
• Salam Hospital
• MOH Oncology Centers
• Clinical Pharmacy Students (100 hr)
• SCOPS
• Helwan
115 Sherif kamal 2010
![Page 116: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/116.jpg)
Training Program
• This program will discuss aspects of Clinical Pharmacy and pharmaceutical care with particular emphasis on the application in the hospital.
• The duration of the program will be 2 Weeks (100 hrs) from Sunday – Thursday, 8 hours each day, where there will be lectures (1 hr min x5 lectures= 5 hrs), on the job training (OJT) (8 hr X 10 days= 80hrs) and 15 hrs final project .
• During the OJT the trainee will be rotated to work in the different areas of the Department of pharmaceutical services in hospital 57357.
• The participant will undergo pre and post-lecture Exams and will be evaluated at the different work sites, each trainee will be assigned to make a project with a final exam written.
• The project assignment will be the development of Pharmaceutical Care Plans for the patients and Study proposal.
116 Sherif kamal 2010
![Page 117: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/117.jpg)
![Page 118: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/118.jpg)
![Page 119: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/119.jpg)
![Page 120: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/120.jpg)
![Page 121: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/121.jpg)
![Page 122: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/122.jpg)
Cairo 100 hr Perceptorshipand Academic Platform
![Page 123: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/123.jpg)
![Page 124: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/124.jpg)
![Page 125: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/125.jpg)
Helwan University
![Page 126: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/126.jpg)
![Page 127: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/127.jpg)
![Page 128: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/128.jpg)
Sherif kamal 2010
![Page 129: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/129.jpg)
MISK
![Page 130: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/130.jpg)
![Page 131: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/131.jpg)
DPS 2020
131 Sherif kamal 2010
![Page 132: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/132.jpg)
![Page 133: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/133.jpg)
![Page 134: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/134.jpg)
![Page 135: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/135.jpg)
![Page 136: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/136.jpg)
![Page 137: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/137.jpg)
![Page 138: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/138.jpg)
Sherif kamal 2010
![Page 139: Austria 1652011](https://reader035.fdocuments.net/reader035/viewer/2022081505/55517300b4c905723b8b4e4b/html5/thumbnails/139.jpg)
139 Sherif kamal 2010